Penn Pancreatic Cancer Research Center

Clinical Trials

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or Patricia.Gambino@uphs.upenn.edu to make an appointment with one of our Oncologists to discuss clinical trials. 

Neoadjuvant Trials — Pre-operative

Trial #

Trial

Type of therapy

Description

Principal Investigator

22217

gemcitabine/cisplatin/nab-paclitaxel/nivolumab with or without vitamin D

 

neo-adjuvant -resectable

 

 

Perioperative Nivolumab and Paricalcitol in Resectable Pancreatic Cancer

 

Peter O’Dwyer, MD
Adjuvant Trials — Post-operative

Trial #

Trial

Type of therapy

Description

Principal Investigator

Currently no trials         
Locally Advanced

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 32213 Radiation & nab®-Paclitaxel Radiation & Chemotherapy A phase I dual dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer Edgar Ben-Josef, MD
Metastatic trials-First Line (Initial treatment for newly metastatic diagnosis)

Trial #

Trial

Type of therapy

Description

Principal Investigator

07220 AB680 (CD73 inhibitor), AB122 (PD-1 inhibitor) 1st line metastatic Phase l Study: evaluate safety of AB680 in patients w/Gastrointestinal malignancies. Gem/Abraxane & CD73 inhibitor Mark O'Hara, MD

Maintenance Therapy

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 35217 (NCT03404960) PARPVAX   Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy   
Metastatic Trials — Second Line

Trial #

Trial

Type of therapy

Description

Principal Investigator

21219
 

SM-88 or SOC

 

 

1st & 2nd line - Metastatic Pancreatic Cancer

 

 

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

 

Gregory Beatty, MD
Metastatic Trials — Third Line

Trial #

Trial

Type of therapy

Description

Principal Investigator

Currently no trials         
Biomarker Trials

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 22210 Pancreatic Tissue Acquisition No Therapy Protocol to permit the acquisition of samples of tumor and normal tissue for biological endpoints in pancreatic cancer Peter O`Dwyer, MD
UPCC 02215 Circulating Tumor Material No Therapy Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases and Control Subjects Peter O`Dwyer, MD

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or patricia.gambino@uphs.upenn.edu to make an appointment with one to discuss clinical trials.

 

Please note that openings for clinical trials are highly variable. Consequently, at any given time there may not be open slots for the trials shown here. Conversely, slots may be available for clinical trials that have not yet been listed on this page. To determine whether a clinical trial may be appropriate for you, please contact your Abramson Cancer Center Oncologist at 1-800-789-7366.

 

 

© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Report Accessibility Issues and Get Help | Privacy Policy | Site Design: DART Web Team.